SCIENCE AT THE SPEED OF BUSINESS

Our fundamental premise is that innovative methods, analytical rigor, and scientific acumen can be provided in a commercial entity that operates “at the speed of business.” Monument Analytics delivers.

Unparalleled Knowledge Base

One of the most remarkable features of Monument Analytics is its access to consultants with an unparalleled knowledge base. Through its independent consulting services, Monument Analytics leverages this acumen to assist clients developing products and services for the benefit of society.

Top Notch Evidence

By capitalizing on this unparalleled depth and breadth of human capital, Monument Analytics is able to generate the highest quality evidence regarding the safety, effectiveness, and real-world value of the full range of medical processes and technologies; and to use this knowledge to help our clients navigate evermore complex and challenging regulatory and payment environments.

Internationally Renowned Experts

Our Principals and Consultants are internationally renowned for their expertise in areas ranging from epidemiology and biostatistics to clinical fields such as cardiovascular medicine, oncology, and immunology.

G. Caleb Alexander
G. Caleb AlexanderMD, MS
CO-FOUNDER & PRINCIPAL
Jonothan C. Tierce
Jonothan C. TierceCPhil
CO-FOUNDER & PRINCIPAL
William V. Padula
William V. PadulaPhD
PRINCIPAL
Natalie Reid
Natalie ReidPhD, MPH, MBA
DIRECTOR
MEET THE CONSULTING TEAM

Services

Our services are broadly organized into four core capabilities

  • Comparative effectiveness analyses
  • Pharmacovigilance and safety assessments
  • Investigations of drug utilization
  • Risk-benefit appraisals
  • Bayesian, meta-analytic and systematic reviews
  • Patient and clinician preferences
  • Global marketplace and pharmaceutical policy
  • Design and conduct of sophisticated comparative effectiveness, pharmacovigilance, and drug utilization studies
  • Advanced techniques for causal inference, management of missing data, and other statistical analysis
  • Cost-benefit analysis and cost-effectiveness analysis
  • Natural history of disease and resource utilization
  • Systematic economic and quality-of-life reviews
  • Core value dossiers

MA in the News

March 20, 2022  Caleb Alexander
MMonument Analytics Co-Founder and Principal Dr. Caleb Alexander was interviewed in a segment of Full Measure with Sharyl Attkisson titled: “Mind Games” about the FDA’s approval of Aduhelm.

WVXU

March 15, 2022  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was featured in a segment of the Cincinnati Edition titled: “Alzheimer’s groups speak out against proposed Medicare restrictions on controversial drug.” Dr. Alexander discussed his perspective as a member of the FDA advisory panel that reviewed two clinical trials related to Aduhelm.

SowetanLive

February 23, 2022  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was quoted in the Sowetan Live article: “Are people on immunosuppressive drugs more susceptible to severe Covid-19?

February 23, 2022
Monument Analytics Team Members: William V. Padula, Natalie M. Reid, Benjamin G. Cohen, Francine Chingcuanco, Jeromie Ballreich, Jonothan Tierce, and G. Caleb Alexander
A paper co-authored by Monument Analytics team members in the Journal of Medical Economics titled: “Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis” was selected as one of the Deputy Editor-in-Chief’s top three papers in 2021.

JWC

February 11, 2022
Monument Analytics Team Members: Benjamin G. Cohen, Natalie M. Reid, and William V. Padula
Monument Analytics team members co-authored an article in the Journal of Wound Care titled: “Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment.”

February 8, 2022  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was featured in an article in Law360 titled: “Opioid Crisis In Wash. State ‘Unique,’ Judge Told” for his abatement plan expert testimony in the Washington State opioid trial.

SEE ALL MA NEWS